Background and Purpose Several studies are currently evaluating tissue-type plasminogen activator (TPA) as a potential therapy in acute ischemic stroke. The possibility of inducing intracranial hematomas, however, introduces an important concern into ultimate evaluation of risk and benefit. This retrospective analysis sought to identify factors associated with intracranial hematoma formation in a pilot phase 1 study of TPA for stroke.
Methods Ninety-four patients received TPA within 3 hours of the onset of an acute ischemic stroke. Five of these patients developed a symptomatic intracerebral hematoma: 3 of 74 (4%) among patients treated within 90 minutes of stroke onset and 2 of 20 (10%) among those treated at 91 to 180 minutes. Three of the 5 died within 2 weeks. The analysis investigated associations between clinical factors and intracerebral hematomas.
Results Factors significantly related to the development of an intracerebral hematoma were TPA dose and diastolic hypertension. Intracerebral hematomas developed in 4 (18%) of 22 patients given a TPA dose of at least 0.90 mg/kg versus only 1 hematoma in the remaining 72 patients (1%; P<.02, Fisher's exact test). Four (18%) of 22 patients who had initial diastolic blood pressures of at least 100 mm Hg suffered an intracerebral hematoma versus only 1 (1%) of 72 patients (P<.02) with lower initial diastolic pressures.
Conclusions Since the study was not designed to test specific safety hypotheses, results must not be overinterpreted. Nonetheless, these data emphasize the need for caution in both patient and dose selection for further studies of thrombolytic agents in stroke. for acute myocardial infarction (MI). In the United States, the most common thrombolytic agent for MI is tissue-type plasminogen activator (TPA). TPA is also the subject of several ongoing clinical trials to assess efficacy and safety in acute ischemic stroke. Knowledge of the fibrinolytic mechanism of the agent and experience with MI have raised concern that excessive intracranial bleeding might limit or contraindicate its use in ischemic stroke. As currently approved in the United States, TPA is contraindicated in MI patients with a "history of a cerebrovascular accident" (as stated in the package insert).
Two open-label, phase 1 studies in the United States assessed different aspects of the safety and efficacy of recombinant TPA: one sponsored by the National In-stitutes of Health (NIH) studied single-stranded TPA (alteplase), and the other reported by the TPA Acute Stroke Study Group (ASSG) studied double-stranded TPA (duteplase). The latter trial, published by del Zoppo et al 1 and Wolpert et al, 2 provided tentative evidence of enhanced recanalization of occluded cerebral arteries when TPA was given within the first 8 hours after stroke onset. The NIH trial required more immediate treatment, initially within 90 minutes and subsequently in a 91-to 180-minute time window. Results of the NIH trials have been published by Brott et al 3 for the 0-to 90-minute window and by Haley et al* for the 91-to 180-minute window. They suggest that TPA is relatively safe and warrants further study for efficacy.
Nonetheless, intracranial hemorrhage did occur in both the ASSG and NIH trials. In the ASSG report, 2 32 (35%) of 93 patients given TPA within 8 hours of stroke onset had evidence of blood on a computed tomogram (CT) done at 24 hours; 21 (23%) were categorized as hemorrhagic infarctions (regions with barely visible increased density with indistinct margins) and 11 (12%) as parenchymal hematomas (very dense, circumscribed regions). In the NIH trial, three symptomatic intracerebral hematomas (parenchymal hemorrhages) were documented clinically and by CT (within 24 hours) in the 0-to 90-minute group of 74 patients (4%) and two in the 91-to 180-minute group of 20 patients (10%). This article examines factors that may have been related to the formation of intracerebral hematomas in the NIH study.
Subjects and Methods
Patients with acute ischemic stroke were recruited at The New York Hospital-Cornell Medical Center, the University of Virginia Medical Center, the Winchester (Virginia) Medical Center, the University of Cincinnati Medical Center, and eight other greater Cincinnati hospitals from February 1987 through December 1989. To be eligible, patients aged 18 to 80 years were required to have a diagnosis of acute cerebral ischemia producing a serious measurable deficit, with established onset within 90 minutes of treatment (180 minutes after November 1988). Among the exclusion criteria were any evidence of parenchymal or subarachnoid hemorrhage on a pretreatment CT scan of the head and coagulation variables or interventions likely to create an excessive risk of bleeding. Patients anticoagulated with warfarin or heparin were excluded, but those on aspirin were not. Hypertensive patients were also excluded if a pretreatment blood pressure in the hospital was above 200 mm Hg systolic or 120 mm Hg diastolic; this criterion was changed during the study to exclude patients with a mean blood pressure (diastolic pressure plus one third of the pulse pressure) above 133 mm Hg.
In addition to a pretreatment medical and neurological evaluation, electrocardiogram (ECG), unenhanced head CT scan, routine blood chemistries and hematologic variables (including platelet count), and prothrombin time and activated partial thromboplastin time, patients underwent standardized scoring of their neurological deficit with the NIH Stroke Scale 3 (0, normal; 42, maximal impairment). The potential risks of fibrinolytic therapy were explained to the patient and whenever possible to a family member (always, in the presence of language or cognitive impairment), and informed consent was obtained in accordance with local institutional review board criteria.
Single-stranded, recombinant TPA (rTPA; alteplase provided by Genentech, South San Francisco, Calif) was then administered intravenously in accordance with a defined doseescalation schedule; the experience at each dose tier was reviewed by an independent safety and data monitoring committee (John Hallenbeck, MD, PhD; Thomas Price, MD; David Stump, MD) before the next dose began. Binding criteria for dose escalation were not established before study onset because of the lack of knowledge about TPA in stroke in 1986, but it was decided that two major bleeding complications per group of six consecutive patients would require reduction of the dose by one tier pending further review (as occurred at a dose of 0.95 mg/kg over 60 minutes). The dose tiers used in the 0-to 90-and 91-to 180-minute patients (Table 1 ) differed in terms of dose calculated per patient, maximum dose permitted per patient, the basis for dosage calculation (either body weight in kilograms or body surface area in square meters), and the infusion schedule (either 60 minutes or 90 minutes, the latter with an initial 30-minute bolus). Post-rTPA heparin was not permitted for at least 1 hour after the end of the rTPA infusion and only if a posttreatment CT showed no evidence of new intracranial hemorrhage.
The primary end points and analytic techniques have already been described. 34 As a safety end point, intracerebral hematoma was distinguished from hemorrhagic conversion by requiring either contemporaneous neurological worsening or a new mass effect on CT for intracerebral hematoma. Hemorrhagic conversions are not analyzed in this article. Because the study was not designed to test hypotheses about causes of intracerebral hematomas, none of the following results should be considered to establish causality but should be taken only to suggest factors that may correlate with intracerebral hematoma.
Univariate comparisons of independent variables believed to bear a possible relation to hematoma were conducted with Student's t tests for normally distributed data, the Wilcoxon test for nonnormal data, and the x 2 o r Fisher's exact test for categorical data. For multivariate analysis, a logistic model was fitted to the data to assess the relative contribution of multiple variables to intracerebral hematomas. Finally, a correlation analysis was performed, with Spearman's correlation coefficients used to indicate the strength of association between variables and hematoma. Continuous data are presented as mean±SD. In view of the exploratory nature of these analyses, corrections for multiple comparisons were not made. Probability values are provided when less than .10 in part because of concern about a type 2 error given the small number of hemorrhages; they should be taken only as indications of possible relations.
Results
Intracerebral hematomas occurred in 5 (5%) of the 94 patients (Table 2) . Initial symptoms leading to detection of the hematomas were observed at 50,60,60,65 minutes, and 10 hours after the end of the TPA infusion. Two of these 5 patients died within the first week without any surgery attempted, and another died during the second week. The 2 survivors were living at home with moderate impairment at 3 months, although 1 (patient 4) had required a suboccipital craniotomy followed by a reexploration for a cerebellar hematoma. Prior cerebrovascular events were reported in 3 of these patients (patient 1: a transient ischemic attack [TLA] 1 hour before the index stroke; patient 4: an old left caudate infarct; and patient 5: an old right parietal infarct; the temporal relation of these infarcts to the index stroke was not available, and baseline CT scans showed no evidence of the earlier strokes.) Two serious systemic hemorrhages also occurred. A patient with an MI 5 days earlier developed hemopericardium and cardiac tamponade in the setting of hypofibrinogenemia (fibrinogen less than 100 mg/dL for at least 6 hours); the hemopericardium was successfully aspirated without sequelae. The other patient, who had undergone transfemoral angiography for a TLA and suffered a stroke during the angiogram, developed a retroperitoneal hemorrhage 1 day after receiving TPA and 12 hours after beginning intravenous heparin. This woman improved without further therapy and was normal at 3 months.
Several lines of evidence address the relation of intracerebral hematoma to vascular recanalization. Only 1 patient had an autopsy, and that 67-year-old woman's occluded artery was still occluded at the time of her death. Angiograms were available in 1 other patient with an intracerebral hematoma, and that patient also remained occluded. In 2 other patients, the hemorrhage was in an area of brain not affected by the index stroke (cerebellar hemorrhage in one and contralateral cerebral hemispheric hemorrhage in the other). Taken together, these observations suggest that bleeding was not related to reperfusion caused by the thrombolytic therapy.
Except for baseline blood pressure and TPA dose, multiple analyses of most of the individual variables versus intracerebral hematoma (Tables 3 and 4) failed to reveal a significant association. Despite the apparently different intracerebral hematoma rates in the two treatment intervals (4% for 0 to 90 minutes versus 10% for 91 to 180 minutes), the time to treat did not differ significantly in patients with and without hematomas. In terms of blood pressure ( The relation between TPA dose and intracerebral hematoma, however, is more complex. Patients in dose tiers at or above tier IV extended (ie, those given at least 0.95 mg/kg; Table 3 ) had a significantly increased risk of hematoma formation compared with those at lower tiers, but there was no relation to the total dose of TPA in milligrams (Table 3) . When calculated as dose per kilogram body weight, the relation was also significant (Table 3) ; specifically, intracerebral hematomas were seen in 4 (18%) of 22 patients given a dose of at least 0.90 mg/kg versus only 1 hematoma in the remaining 72 patients (1%; P<.01, x 2 and P<.02, Fisher's). There was no relation if dose was analyzed on the basis of body weight (Table 3) . To further clarify the discrepancy between the nonsignificance of total dose and the significance of dose per kilogram, the relation to weight was assessed and found also to be marginally significant (P<.10, Table 3 ), with lighter patients more likely to develop hematomas than heavier ones.
Variables found by Spearman's correlation coefficients to bear a possible relation to hematoma formation were elevated initial diastolic pressure (P<.01), increasing dose tier (P<.02), lower body weight (P<AQ), and lower (better) initial cardinal sign (the clinical abnormality most indicative of the patient's pretreatment neurological deficit; P<.10).
Two variables emerged from a multivariate stepwise logistic procedure as meeting the .05 significance level for entry into the model. These were the initial diastolic blood pressure and the dose per kilogram body weight. (The same two variables emerged from a backward elimination logistic procedure.) It should be noted that prior aspirin use initially entered the model but was subsequently removed. The model, moreover, was not highly predictive of hematoma: although the specificity was 99%, the sensitivity was only 20%; the falsenegative rate was 5%, but the false-positive rate was 50%.
A correlation analysis of 10 variables (age, sex, cardinal sign, initial diastolic pressure, height, weight, body surface area, total dose, dose tier, and baseline Stroke Scale score) yielded possibly significant associations (P<A0) only for initial diastolic pressure (.P<.01), dose tier (P<.02), and weight and cardinal sign (P<A0 for each).
Discussion
The relatively small number of patients with intracerebral hematomas in these two trials poses a problem in attempting to analyze factors related to bleeding. This has also been true for other attempts to clarify risk factors for bleeding, whether in MI patients 6 " 18 or in stroke patients. 2 -19 For stroke, one additional feature complicating the situation is the occurrence of intracranial bleeding in patients with ischemic stroke who receive no specific therapy (eg, Hornig et al 20 ) . As already noted, vascular reperfusion did not appear to be related to intracerebral hematomas, but two other factors emerged as being related to hematoma formation: TPA dose and initial diastolic blood pressure.
Studies of factors related to bleeding in the larger experience of patients receiving TPA for MI largely support the findings in the present study, although it must be remembered that heparin was used along with TPA in most of the MI trials. In the experience of Braunwald et al 21 in the Thromborysis in Myocardial Infarction Trial, 1.6% of 1014 patients receiving 150 mg TPA experienced intracranial bleeding versus only 0.6% of 1452 patients given 100 mg. The possible risk in stroke patients of TPA doses approaching 100 mg is supported by the recent report of von Kummer and Hacke, 19 in which fatal parenchymal hemorrhage occurred in 3 (9%) of 32 ischemic stroke patients given 100 mg of TPA intravenously within 6 hours of stroke onset, a rate somewhat higher than ours of 5 (5%) of 94. On the other hand, del Zoppo et al, 1 reporting on the ASSG, could not find a relation between intracranial bleeding and TPA dose. We never achieved a TPA dose of 150 mg in our trial, and possibly as a result the relation of bleeding to dose is somewhat less clear-cut than in the MI experience.
Exploring the relation between TPA dose and bleeding is further complicated by different ways of reporting dose. DeJaegere et al 15 performed a case-control study of MI patients in the Netherlands who had intracranial hemorrhages while being treated with thrombolytic agents. Patients with a body weight less than 70 kg were nearly four times more likely to have an intracranial hemorrhage than heavier patients. Based in part on these data, Sloan and Price 8 suggested that some of the relation between bleeding and dose might be a consequence of greater systemic effects (including drug concentration) in individuals with lower body weights. Our data for dose per kilogTam, however, suggest that the relation of dose to bleeding holds even when corrected for body weight. Thus, physicians tempted to treat stroke patients with TPA should be very cautious in approaching doses of TPA currently being used for MI patients because our experience suggests that doses as low as 90 to 100 mg might increase bleeding risk.
As just discussed, our data suggest, but do not prove, a somewhat increased risk of bleeding in patients with lower body weight, independent of the TPA dose used. Although a similar finding was reported in MI patients by Bovill et al, 10 Califf et al, 22 and DeJaegere et al, 15 the failure in these MI studies to base TPA dose on body weight or surface area leaves open the possibility that greater bleeding in lighter patients seen in those studies could simply have been a dose effect. In contrast, our data support the possibility that lighter patients may have a greater risk of bleeding independent of the TPA dose used.
Other hematologic variables have not clearly been implicated in the risk of bleeding in patients given TPA. As reported by Kase et al, 7 we found no relation of bleeding to hypofibrinogenemia, an observation indirectly supported by the lack of any symptomatic intracranial bleeding in 132 stroke patients recently randomized to placebo and ancrod, 23 an agent with a predominant defibrinogenating action. Although Kase et al 7 and Bovill et al 10 reported a possible association of bleeding with activated partial thromboplastin time, we did not uniformly measure that variable. An association of bleeding with heparin used in conjunction with a thrombolytic for MI has been reported by ISIS-3 (Third International Study of Infarct Survival), 24 GISSI-2, and heparin concurrently within 6 hours of stroke onset by von Kummer and Hacke, 19 only three (9%) developed parenchymal hematomas. This is not different from the incidence of parenchymal hematoma among our patients in the 91-to 180-minute group.
The review by Sloan and Price 8 suggests a relation between older age and intracranial hemorrhage, and data by Maggioni et al, 12 Califf et al, 22 Gore et al, u Anderson et al, 9 and DeJaegere et al 15 are supportive. Our data do not confirm this relation in patients receiving thrombolytic agents for stroke. None of the five intracranial hematomas in our patients occurred in individuals aged older than 75 years, and three patients were aged younger than 70 years. Moreover, in the one patient who came to autopsy, there was no evidence of amyloid angiopathy, a factor suggested by some 13 as predisposing to bleeding in this setting. (The only surgical specimen showed "small blood clots, no other abnormalities, and normal bone fragments" and is thus not helpful in evaluating the possible role of amyloid angiopathy.)
Our data do not establish a greater risk of intracerebral hemorrhage with longer intervals to treat, possibly because most of our patients were treated within 90 minutes and all within 3 hours of stroke onset. In contrast, del Zoppo et al 1 and Wolpert et al 2 reported that when intracerebral hematoma and hemorrhagic transformation were grouped and the interval to begin TPA for stroke was compared in patients with either type of hemorrhage, a relation between bleeding and interval to treat was demonstrated. They found that the interval was longer (6.1 ±1.5 hours) in those with hemorrhage than in those without (5.3±1.7 hours), and an alternate analysis revealed intracranial bleeding in 15 (25%) of 61 patients treated within 6 hours and 17 (53%) of 32 patients treated at 6 to 8 hours (P<.02).
A possible relation of bleeding to hypertension has been demonstrated by Anderson et al 9 with streptokinase and TPA and is cited in the review by Sloan and Price. 8 Although Gore et al 11 noted intracerebral hemorrhages in more patients with a history of hypertension (0.9%) than without (0.4%), the difference was not significant. A recent abstract by Selker et al 27 demonstrates a greater relation of intracranial hemorrhage to pulse pressure than to diastolic, systolic, or mean blood pressure in MI patients treated with thrombolytics, but our data do not support a relation to pulse pressure. Instead, our results raise concerns about using thrombotytics in stroke patients with high blood pressure, although the relation seemed most apparent with diastolic pressure. While relations like these of intracranial hemorrhage to high baseline blood pressure are not surprising, precise blood pressure criteria to be used in guiding thrombolytic therapy are not yet established. Additional factors that will require attention, moreover, include effectiveness of antihypertensive therapy given in conjunction with TPA and the possible influence of blood pressure lability on the risk of bleeding.
The possibility of serious hemorrhage when thrombolytics are given for stroke makes the risk-benefit ratio for this intervention particularly sensitive. We do not yet know whether TPA will be found to be effective in acute stroke. Along with suggestions of efficacy that are emerging from these early studies, we are also seeing potentially serious adverse effects. As various investigative groups accumulate more experience with TPA (and other thrombolytics) in acute stroke, more definitive contraindications and warnings should emerge. Our experience with a stepwise logistic model, however, suggests that accurate prediction of patients at risk will be limited at best. To date, the rate of intracranial hemorrhage has been relatively small in most trials, but this experience with thrombolytics has been in carefully monitored trials. Even so, factors that might promote bleeding are being identified; these include hypertension, TPA dose, and interval to treat (at least if longer than 6 hours). Equal or even greater care will be required in patient selection and management protocols for future trials, and this diligence must be translated to all practicing neurologists if and when thrombolytic agents are approved for use in acute ischemic stroke.
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